Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva appoints general manager in Germany

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industries has made several appointments in Germany following its acquisition of Ratiopharm. It appointed Dr Sven Dethlefs, previously CEO of Teva Germany, as general manager of Ratiopharm. Oliver Windholz, Ratiopharm's former chairman, will oversee integration of Teva's European headquarters in Utrecht, the Netherlands, as chief operating officer until the end of this year, after which will leave the company. Dr Walter Buhl will continue as head of production in Germany, and Dr Gerald Huber will take over Teva's R&D operations in Europe. Dr Hermann Allgaier will head late-stage commercial production of Ratiopharm's biopharmaceutical and biogeneric products after its integration into Teva's business, and Dr Karl Heinz Emmert will be responsible for the development of biosimilars.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts